Literature DB >> 26732472

Immune Checkpoint Blockade in Hepatocellular Carcinoma.

M Kudo1.   

Abstract

Entities:  

Year:  2015        PMID： 26732472      PMCID： PMC4698623          DOI： 10.1159/000367758

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  35 in total

1.  Tumor immunotherapy directed at PD-1.

Authors:  Antoni Ribas
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 2.  Local ablation for hepatocellular carcinoma in taiwan.

Authors:  Shi-Ming Lin
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 4.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Curr Opin Immunol       Date:  2012-01-09       Impact factor: 7.486

Review 5.  Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

Authors:  George K Philips; Michael Atkins
Journal:  Int Immunol       Date:  2014-10-16       Impact factor: 4.823

6.  Cancer immunotherapy highlights from the 2014 ASCO Meeting.

Authors:  Lauren C Harshman; Charles G Drake; Jennifer A Wargo; Padmanee Sharma; Nina Bhardwaj
Journal:  Cancer Immunol Res       Date:  2014-08       Impact factor: 11.151

7.  Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.

Authors:  Qiang Gao; Xiao-Ying Wang; Shuang-Jian Qiu; Ichiro Yamato; Masayuki Sho; Yoshiyuki Nakajima; Jian Zhou; Bai-Zhou Li; Ying-Hong Shi; Yong-Sheng Xiao; Yang Xu; Jia Fan
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307
View more
  11 in total

1.  Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

Review 2.  Therapy in Advanced Hepatocellular Carcinoma.

Authors:  Hanna Javan; Farshid Dayyani; Nadine Abi-Jaoudeh
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 3.  How does the tumor microenvironment play a role in hepatobiliary tumors?

Authors:  Fathima Kamil; Julie H Rowe
Journal:  J Gastrointest Oncol       Date:  2018-02

4.  Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.

Authors:  Valerie Chew; Liyun Lai; Lu Pan; Chun Jye Lim; Juntao Li; Raymond Ong; Camillus Chua; Jing Yao Leong; Kiat Hon Lim; Han Chong Toh; Ser Yee Lee; Chung Yip Chan; Brian K P Goh; Alexander Chung; Pierce K H Chow; Salvatore Albani
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-03       Impact factor: 11.205

Review 5.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

6.  Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?

Authors:  Jane Margetts; Laura F Ogle; Stephen L Chan; Anthony W H Chan; K C Allen Chan; David Jamieson; Catherine E Willoughby; Derek A Mann; Caroline L Wilson; Derek M Manas; Winnie Yeo; Helen L Reeves
Journal:  Br J Cancer       Date:  2017-11-09       Impact factor: 7.640

7.  CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage.

Authors:  Kuan Hu; Zhi-Ming Wang; Juan-Ni Li; Sai Zhang; Zhong-Fu Xiao; Yi-Ming Tao
Journal:  Transl Oncol       Date:  2018-03-08       Impact factor: 4.243

8.  High Blood miR-802 Is Associated With Poor Prognosis in HCC Patients by Regulating DNA Damage Response 1 (REDD1)-Mediated Function of T Cells.

Authors:  Chao Jiang; Xueyan Liu; Meng Wang; Guoyue Lv; Guangyi Wang
Journal:  Oncol Res       Date:  2019-04-12       Impact factor: 5.574

Review 9.  Challenges of advanced hepatocellular carcinoma.

Authors:  Stefano Colagrande; Andrea L Inghilesi; Sami Aburas; Gian G Taliani; Cosimo Nardi; Fabio Marra
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

10.  B7-H4 overexpression is essential for early hepatocellular carcinoma progression and recurrence.

Authors:  Fu-Biao Kang; Ling Wang; Dian-Xing Sun; Hai-Jun Li; Dong Li; Yan Wang; Ji-Wen Kang
Journal:  Oncotarget       Date:  2017-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.